Condition: Myasthenia Gravis · Myasthenia Gravis, MuSK · Sponsor: NMD Pharma A/S
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
This description comes directly from the study's public registry record.
NMD Pharma A/S · contact@nmdpharma.com · contact@nmdpharma.com
Always discuss trial participation with your own doctor first.
| Profound Research LLC | Carlsbad, California, United States | Withdrawn |
| University of California Irvine Medical Center | Irvine, California, United States | Recruiting |
| University of Colorado Neuromuscular Division | Aurora, Colorado, United States | Recruiting |
| SFM Clinical Research, LLC | Boca Raton, Florida, United States | Recruiting |
| Neuromuscular Research Division | University of South Florida | Tampa, Florida, United States | Recruiting |
| Augusta University, Neuroscience Center | Augusta, Georgia, United States | Recruiting |
| NextGen Precision Health | Columbia, Missouri, United States | Recruiting |
| The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
| University of Oregon | Portland, Oregon, United States | Recruiting |
| Semmes Murphey Clinic | Memphis, Tennessee, United States | Recruiting |
| UZ Leuven | Leuven, Belgium | Withdrawn |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06414954